BioVie Inc - Ordinary Shares - Class A
BIVI
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.58M
Close$
$3.92
172.5% upside
Current Fair Value
172.5% upsideUndervalued by 172.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.58 Million |
|---|---|
| Enterprise Value | $772,051.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.12 |
| Beta | 0.58 |
| Outstanding Shares | 7,543,923 |
Return
| Return on Equity | -127.89% |
|---|---|
| Return on Assets | -113.96% |
| Return on Invested Capital | -126.81% |
Valuation & Multiples
| P/E Ratio | -1.22 |
|---|---|
| PEG | -1.38 |
| Price to Sales | - |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.66%▼ 0.98% |
|---|---|
| Total Invested | $1.44M▲ 7.26% |
| Investors Holding | 32▼ 3.00% |
ESG Score
No data
About BioVie Inc
3 employeesBioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity i...